sessed at screening, baseline (randomization,Day 1), and study end point (Day 28). Allblood, plasma, and serum samples were ana-lyzed by a central laboratory (Quintiles Labo-ratories, Smyrna, GA). HbA 1cwas measured by a high-performance liquid chromatographymethod (Bio-Rad Laboratories, Hercules, CA). 9 Adverse events were collected and noted ateach patient visit throughout the study. Hypo-glycemic symptoms that were reported by sub-jects that were accompanied with a docu-mented blood glucose measurement of /H1102160